TERPENOID THERAPEUTICS, INC.

Basic Information

2501 Crosspark Road
Room B126-MTF
CORALVILLE, IA, 52241-3471

http://www.terpenoid.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 602743903
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 7


  1. Targeting the chondrosarcoma extracellular matrix for drug delivery

    Amount: $222,881.00

    DESCRIPTION (provided by applicant): Chondrosarcoma is the second most common primary tumor of the bone having an incidence of 8 per million people in the US population over age 80. Research, particu ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Polaris Oncology Survivor Transition (POST) System

    Amount: $163,134.00

    DESCRIPTION (provided by applicant): The goal of these studies is to determine the efficacy of proprietary geranylgeranyl diphosphate synthase inhibitors (GGSIs), for inhibition of osteoclast mediated ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Schweinfurthins: novel treatment for breast cancer

    Amount: $204,000.00

    DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 182,000 cases of invasive breast cancer occurred in the US in 2008, with 40,000 deaths due to breast cancer. ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. Improving the Distribution of Geranylgeranyl Diphosphate synthase inhibitors.

    Amount: $114,959.00

    DESCRIPTION (provided by applicant): The goal of these studies is the development of a treatment for hormone refractory prostate cancer based on the inhibition of an enzyme geranygeranyl disphosphate ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Developing Schweinfurthin Analogs as Glioma Therapies

    Amount: $670,417.00

    DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 21,810 cases of primary malignant brain tumor will be reported in the US in 2008. The ACS also estimates that ...

    STTR Phase II 2009 Department of Health and Human Services
  6. Novel Glioblastoma Therapeutics

    Amount: $109,860.00

    DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of developing therapies for brain cancers such as glioblastoma multiforme from the schwein ...

    STTR Phase I 2007 Department of Health and Human Services
  7. Preclinical Development of Geranylgeranyl Disphosphate Synthase Inhibitors as Ant

    Amount: $123,123.00

    DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of moving our novel class of GGDPS specific inhibitors into clinical development for treat ...

    STTR Phase I 2007 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government